Not available outside of the UK & Ireland.
Application
AM251, a CB1 cannabinoid receptor antagonist, has been used in a study to determine its interaction with hippocampal neurons to enhance spatial memory in mice.
Biochem/physiol Actions
AM251 is a CB1 cannabinoid receptor antagonist.
Features and Benefits
This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Other Notes
Salt content may vary.
Packaging
10, 50 mg in glass bottle
This product has met the following criteria to qualify for the following awards: